Show simple item record

dc.contributor.authorLarraga, Jaime
dc.contributor.authorAlcolea, Pedro J
dc.contributor.authorAlonso, Ana M
dc.contributor.authorMartins, Luis T C
dc.contributor.authorMoreno-Iruela, Inmaculada 
dc.contributor.authorDominguez-Rodriguez, Mercedes 
dc.contributor.authorLarraga, Vicente
dc.date.accessioned2022-05-23T11:20:12Z
dc.date.available2022-05-23T11:20:12Z
dc.date.issued2022-02-03
dc.identifier.citationVaccines (Basel). 2022 Feb 3;10(2):231.es_ES
dc.identifier.issn2076-393Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14458
dc.description.abstractLeishmania parasites cause outstanding levels of morbidity and mortality in many developing countries in tropical and subtropical regions. Numerous gene expression profiling studies have been performed comparing different Leishmania species' life-cycles and stage forms in regard to their distinct infective ability. Based on expression patterns, homology to human orthologues, in silico HLA-binding predictions, and annotated functions, we were able to select several vaccine candidates which are currently under study. One of these candidates is the Leishmania infantum ubiquitin-conjugating enzyme E2 (LiUBC1), whose relative levels, subcellular location, in vitro infectivity in the U937 myeloid human cell model, and protection levels in Syrian hamsters against L. infantum infection were studied herein. LiUBC1 displays a low level of similarity with the mammalian orthologs and relevant structure differences, such as the C-terminal domain, which is absent in the human ortholog. LiUBC1 is present in highly infective promastigotes. Knock-in parasites overexpressing the enzyme increased their infectivity, according to in vitro experiments. Syrian hamsters immunized with the recombinant LiUBC1 protein did not show any parasite burden in the spleen, unlike the infection control group. The IFN-γ transcript levels in splenocytes were significantly higher in the LiUBC1 immunized group. Therefore, LiUBC1 induced partial protection against L. infantum in the Syrian hamster model.es_ES
dc.description.sponsorshipThis work was financed by a contract with CZ Vaccines, Porriño, Spain, and partially defrayed by a grant from the Fundación Ramón Areces. JL thanks CZ Vaccines for the fellowship.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectLeishmaniaes_ES
dc.subjectInfectiones_ES
dc.subjectUbiquitin-conjugating enzyme E2es_ES
dc.subjectVaccineses_ES
dc.titleLeishmania infantum UBC1 in Metacyclic Promastigotes from Phlebotomus perniciosus, a Vaccine Candidate for Zoonotic Visceral Leishmaniasises_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35214689es_ES
dc.format.volume10es_ES
dc.format.number2es_ES
dc.format.page231es_ES
dc.identifier.doi10.3390/vaccines10020231es_ES
dc.contributor.funderCZ Vaccineses_ES
dc.contributor.funderFundación Ramón Areces es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines10020231es_ES
dc.identifier.journalVaccineses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional